Hecht Beth 4
4 · Xeris Biopharma Holdings, Inc. · Filed Jul 2, 2026
Research Summary
AI-generated summary of this filing
Xeris (XERS) Chief Legal Officer Beth Hecht Sells 16,666 Shares
What Happened
Beth Hecht, Chief Legal Officer and Corporate Secretary of Xeris Biopharma (XERS), sold 16,666 shares on July 1, 2026. The weighted-average sale price was $8.03 per share (range $7.92–$8.19), for total proceeds of approximately $133,860. The filing identifies the transactions as sales (S) and notes the trades were made under a Rule 10b5-1 trading plan adopted August 8, 2025.
Key Details
- Transaction date: July 1, 2026.
- Shares sold: 16,666; weighted avg price: $8.03; price range: $7.92–$8.19. (F2)
- Total proceeds: ~$133,860.
- Plan: Executed under a Rule 10b5-1 trading plan adopted Aug 8, 2025 (F1).
- Shares owned after transaction: not specified in the filing.
- Additional note: Filing references 1,288 shares acquired June 30, 2026 under the issuer’s ESPP (F3).
- Filing timeliness: Report filed July 2, 2026 for a July 1 transaction — within typical Form 4 deadlines (timely).
Context
Sales executed under a 10b5-1 plan are pre-scheduled and are often routine, so they do not necessarily indicate the insider’s current view of the company. This was a modestly sized sale (~$134k) by a senior officer; retail investors should consider this alongside other insider trades and company fundamentals rather than as a standalone signal.
Insider Transaction Report
- Sale
Common Stock
[F1][F2][F3]2026-07-01$8.03/sh−16,666$133,860→ 1,161,128 total
Footnotes (3)
- [F1]The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 8, 2025.
- [F2]The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.92 to $8.19, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
- [F3]Includes 1,288 shares acquired on June 30, 2026 under the issuer's 2018 Employee Stock Purchase Plan, as amended.